{"protocolSection": {"identificationModule": {"nctId": "NCT00546754", "orgStudyIdInfo": {"id": "0954A-333"}, "secondaryIdInfos": [{"id": "MK0954A-333"}, {"id": "2007_031"}], "organization": {"fullName": "Organon and Co", "class": "INDUSTRY"}, "briefTitle": "BP-EASE -Effectiveness of Losartan 50 mg/Hydrochlorothiazide (HCTZ) 12.5 mg Versus Valsartan 80 mg/HCTZ 12.5 mg Titrated as Needed in Patients With Essential Hypertension Not Controlled on Monotherapy (0954A-333)", "officialTitle": "BP-EASE-A 12-Week, Multicenter, Open-Label, Randomized, Controlled Trial To Compare The Effectiveness of Losartan 50 mg/HCTZ 12.5 mg Titrated as Needed to Losartan 100 mg/HCTZ 25 mg or Valsartan 160 mg/HCTZ 25 mg, in Patients With Essential Hypertension Who Have Not Achieved Target Blood Pressure With", "acronym": "EASE"}, "statusModule": {"statusVerifiedDate": "2022-02", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2007-05-01", "type": "ACTUAL"}, "primaryCompletionDateStruct": {"date": "2009-04-01", "type": "ACTUAL"}, "completionDateStruct": {"date": "2009-05-01", "type": "ACTUAL"}, "studyFirstSubmitDate": "2007-10-17", "studyFirstSubmitQcDate": "2007-10-17", "studyFirstPostDateStruct": {"date": "2007-10-19", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2010-03-26", "resultsFirstSubmitQcDate": "2010-03-26", "resultsFirstPostDateStruct": {"date": "2010-04-13", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2024-05-08", "lastUpdatePostDateStruct": {"date": "2024-05-16", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "Organon and Co", "class": "INDUSTRY"}}, "descriptionModule": {"briefSummary": "To evaluate the blood pressure efficacy between losartan and valsartan at equivalent dosage during a 3 months treatment."}, "conditionsModule": {"conditions": ["Hypertension"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE3"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "NONE"}}, "enrollmentInfo": {"count": 808, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "1", "type": "EXPERIMENTAL", "description": "Drug Arm", "interventionNames": ["Drug: losartan potassium (+) hydrochlorothiazide"]}, {"label": "2", "type": "ACTIVE_COMPARATOR", "description": "active comparator", "interventionNames": ["Drug: Comparator: Valsartan (+) Hydrochlorothiazide"]}], "interventions": [{"type": "DRUG", "name": "losartan potassium (+) hydrochlorothiazide", "description": "losartan potassium 50 mg/12.5 Hydrochlorothiazide (HCTZ) titrated as needed to losartan potassium 100 mg/25 mg Hydrochlorothiazide", "armGroupLabels": ["1"]}, {"type": "DRUG", "name": "Comparator: Valsartan (+) Hydrochlorothiazide", "description": "Valsartan 80 mg/ Hydrochlorothiazide 12.5 mg/day titrated as needed to valsartan 160 mg/25 mg Hydrochlorothiazide", "armGroupLabels": ["2"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Change in Systolic Blood Pressure From Baseline to Week 12", "timeFrame": "Baseline and Week 12"}, {"measure": "Change in Diastolic Blood Pressure From Baseline to Week 12", "timeFrame": "Baseline and Week 12"}], "secondaryOutcomes": [{"measure": "Change in Systolic Blood Pressure From Baseline to Week 6", "timeFrame": "Baseline and Week 6"}, {"measure": "Change in Diastolic Blood Pressure From Baseline to Week 6", "timeFrame": "Baseline and Week 6"}, {"measure": "Number of Patients Achieving Target Blood Pressure at Week 6", "description": "Number of Patients Achieving Target Blood Pressure (\\<140/90 mm Hg and \\<130/80 mm Hg for diabetics) at week 6", "timeFrame": "Week 6"}, {"measure": "Number of Patients Achieving Target Blood Pressure at Week 12", "description": "Number of Patients Achieving Target Blood Pressure (\\<140/90 mm Hg and \\<130/80 mm Hg for diabetics) at week 12", "timeFrame": "12 Weeks"}, {"measure": "Time to Achieve Target Blood Pressure", "description": "Time to achieve the target blood pressure (\\<140/90 mmHg and \\<130/80 mmHg for diabetics)", "timeFrame": "12 weeks"}, {"measure": "Change in Uric Acid From Baseline to Week 6", "timeFrame": "Baseline and Week 6"}, {"measure": "Change in Uric Acid From Baseline to Week 12", "timeFrame": "Baseline and Week 12"}, {"measure": "Change in Serum Highly Sensitive C-reactive Protein From Baseline to Week 6", "timeFrame": "Baseline and Week 6"}, {"measure": "Change in Serum Highly Sensitive C-reactive Protein From Baseline to Week 12", "timeFrame": "Baseline and Week 12"}, {"measure": "Change in Gamma-Glutamyl Transpeptidase (Gamma-GT) From Baseline to Week 6", "timeFrame": "Baseline and Week 6"}, {"measure": "Change in Gamma-Glutamyl Transpeptidase (Gamma-GT) From Baseline to Week 12", "timeFrame": "Baseline and Week 12"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* An Adult Patient 18 to 75 Years Of Age\n* Patient with essential hypertension receiving an antihypertensive agent in monotherapy for at least 4 weeks for whom the antihypertensive agent can (and will) be discontinued and whose blood pressure is not controlled:\n* Either systolic or diastolic blood pressure \\> 140/90 mm Hg up to 180/110 mm Hg (inclusive)\n* Either systolic or diastolic blood pressure \\> 130/80 mm Hg up to 160/100 mm Hg (inclusive) for diabetic patients\n* Patient is male or a female who is highly unlikely to conceive as she falls into one of the categories listed below:\n\n  * Surgically sterilized female\n  * Postmenopausal female \\> 45 years of age with \\> 2 years since her last menses\n  * Non-sterilized pre-menopausal female who agrees to: (1) use 2 adequate methods of contraception to prevent pregnancy \\[either 2 barrier methods or a barrier method plus a hormonal method\\]; or (2) abstain from heterosexual activity throughout the study starting with Visit 1 and for 14 days after the last dose of study medication; or (3) only engage in heterosexual activity with surgically sterilized male partner(s) throughout the study starting with Visit 1 and for 14 days after the last dose of study medication\n  * Patient judged to be in otherwise good, stable health on the basis of medical history and physical examination\n\nExclusion Criteria:\n\n* Known secondary hypertension of any aetiology (e.g., uncorrected renal artery stenosis, malignant hypertension, or hypertensive encephalopathy)\n* Patient Needing An Initiation Of A Lipid Lowering Agent Or A Modification Of His Lipid Therapy At Visit 1 Or During The Study Period (12 Weeks)\n* Patient taking allopurinol\n* Patient Previously Shown To Be Intolerant To Any Component Of Losartan Valsartan, Or HCTZ Or With A Documented History Of Angioedema/Anaphylaxis\n* Patient With Confirmed Clinically Significant Renal Or Hepatic Dysfunction And/Or Electrolyte Imbalance Laboratory Test Within The Last 3 Months Prior To Visit 1: Serum Creatinine \\> 130 Umol/L Or Creatinine Clearance \\< 45 Ml/Min, Aspartate transaminase (AST) \\> 2 Times Above The Normal Range, Alanine transaminase (ALT) \\> 2 Times Above The Normal Range, Serum Potassium \\< 3.5 Or \\> 5.5 Meq/L\n* Patient with osteoarthritis who has undergone hip or knee replacement within the last 4 months\n* Patient with chronic inflammatory conditions such as rheumatoid arthritis, lupus, inflammatory bowel disease and those that need a chronic inflammatory therapy such as prednisone or other steroid agents\n* Patient with symptomatic heart failure (classes 3 and 4)\n* Patient with a history of stroke within the last 6 months\n* Patient with coronary heart disease: has undergone percutaneous coronary angioplasty, has had coronary artery bypass, has had past myocardial infarction, all that occurred less than 6 months prior to visit 1 or has unstable angina\n* Patient having participated in an investigational drug program in the last 30 days (prior to Visit 1)\n* Unable or unwilling to comply with the protocol, therefore likely to leave the trial before its completion\n* Patient intends to move or to vacation away from home during the course of the study which would interfere with the scheduled visits.", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "18 Years", "maximumAge": "75 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Medical Monitor", "affiliation": "Merck Sharp & Dohme LLC", "role": "STUDY_DIRECTOR"}]}, "ipdSharingStatementModule": {"ipdSharing": "NO"}}, "resultsSection": {"participantFlowModule": {"recruitmentDetails": "First patient in: MAY-04-2007\n\nLast patient out: APRIL-16-2009\n\nTotal number of sites: 163 sites in Canada", "groups": [{"id": "FG000", "title": "Losartan 50 mg/HCTZ 12.5 mg", "description": "Patients could be titrated up from losartan 50 mg/hydrochlorothiazide (HCTZ) 12.5 mg to losartan 100 mg/HCTZ 25 mg only if needed to achieve target blood pressure."}, {"id": "FG001", "title": "Valsartan 80 mg/HCTZ 12.5 mg", "description": "Patients could be titrated up from valsartan 80 mg/HCTZ 12.5 mg to valsartan 160 mg/HCTZ 25 mg only if needed to achieve target blood pressure."}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "comment": "Number of patients enrolled and randomized", "numSubjects": "425"}, {"groupId": "FG001", "comment": "Number of patients enrolled and randomized", "numSubjects": "383"}]}, {"type": "Treated", "achievements": [{"groupId": "FG000", "comment": "Patients that received at least one dose of study medication and had 1 follow-up visit", "numSubjects": "416"}, {"groupId": "FG001", "comment": "Patients that received at least one dose of study medication and had 1 follow-up visit", "numSubjects": "373"}]}, {"type": "Week 6", "achievements": [{"groupId": "FG000", "numSubjects": "396"}, {"groupId": "FG001", "numSubjects": "347"}]}, {"type": "Week 12", "achievements": [{"groupId": "FG000", "numSubjects": "375"}, {"groupId": "FG001", "numSubjects": "334"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "375"}, {"groupId": "FG001", "numSubjects": "334"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "50"}, {"groupId": "FG001", "numSubjects": "49"}]}], "dropWithdraws": [{"type": "Serious Adverse Event", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "1"}]}, {"type": "Adverse Event", "reasons": [{"groupId": "FG000", "numSubjects": "11"}, {"groupId": "FG001", "numSubjects": "16"}]}, {"type": "Lack of Efficacy", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "1"}]}, {"type": "Lost to Follow-up", "reasons": [{"groupId": "FG000", "numSubjects": "9"}, {"groupId": "FG001", "numSubjects": "15"}]}, {"type": "Protocol Violation", "reasons": [{"groupId": "FG000", "numSubjects": "3"}, {"groupId": "FG001", "numSubjects": "0"}]}, {"type": "Withdrawal by Subject", "reasons": [{"groupId": "FG000", "numSubjects": "6"}, {"groupId": "FG001", "numSubjects": "7"}]}, {"type": "Dyspnea", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "0"}]}, {"type": "Per Data Query, Less Than 4 Wks Coversyl", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "0"}]}, {"type": "Hip Replacement", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "0"}]}, {"type": "Suicide", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "0"}]}, {"type": "Missing Cooperation", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "0"}]}, {"type": "Elevated Creatinine and Potassium levels", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "1"}]}, {"type": "Patient's Decision", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "1"}]}, {"type": "Missing", "reasons": [{"groupId": "FG000", "numSubjects": "14"}, {"groupId": "FG001", "numSubjects": "7"}]}]}]}, "baselineCharacteristicsModule": {"groups": [{"id": "BG000", "title": "Losartan 50 mg/HCTZ 12.5 mg", "description": "Patients could be titrated up from losartan 50 mg/hydrochlorothiazide (HCTZ) 12.5 mg to losartan 100 mg/HCTZ 25 mg only if needed to achieve target blood pressure.\n\n416 number of patients that received at least one dose of study medication and had 1 follow-up visit (intent-to-treat population \\[ITT\\])"}, {"id": "BG001", "title": "Valsartan 80 mg/HCTZ 12.5 mg", "description": "Patients could be titrated up from valsartan 80 mg/HCTZ 12.5 mg to valsartan 160 mg/HCTZ 25 mg only if needed to achieve target blood pressure.\n\n373 - number of patients that received at least one dose of study medication and had 1 follow-up visit (intent-to-treat population \\[ITT\\])"}, {"id": "BG002", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "416"}, {"groupId": "BG001", "value": "373"}, {"groupId": "BG002", "value": "789"}]}], "measures": [{"title": "Age, Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "58.7", "spread": "11.11"}, {"groupId": "BG001", "value": "58.3", "spread": "10.26"}, {"groupId": "BG002", "value": "58.5", "spread": "10.71"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "197"}, {"groupId": "BG001", "value": "180"}, {"groupId": "BG002", "value": "377"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "219"}, {"groupId": "BG001", "value": "193"}, {"groupId": "BG002", "value": "412"}]}]}]}, {"title": "Race/Ethnicity, Customized", "paramType": "NUMBER", "unitOfMeasure": "participants", "classes": [{"title": "Caucasian", "categories": [{"measurements": [{"groupId": "BG000", "value": "364"}, {"groupId": "BG001", "value": "326"}, {"groupId": "BG002", "value": "690"}]}]}, {"title": "Black", "categories": [{"measurements": [{"groupId": "BG000", "value": "8"}, {"groupId": "BG001", "value": "13"}, {"groupId": "BG002", "value": "21"}]}]}, {"title": "Hispanic", "categories": [{"measurements": [{"groupId": "BG000", "value": "2"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "2"}]}]}, {"title": "Asian", "categories": [{"measurements": [{"groupId": "BG000", "value": "34"}, {"groupId": "BG001", "value": "29"}, {"groupId": "BG002", "value": "63"}]}]}, {"title": "Native", "categories": [{"measurements": [{"groupId": "BG000", "value": "4"}, {"groupId": "BG001", "value": "4"}, {"groupId": "BG002", "value": "8"}]}]}, {"title": "East Indian", "categories": [{"measurements": [{"groupId": "BG000", "value": "1"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "1"}]}]}, {"title": "From Middle East", "categories": [{"measurements": [{"groupId": "BG000", "value": "1"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "1"}]}]}, {"title": "Unknown", "categories": [{"measurements": [{"groupId": "BG000", "value": "2"}, {"groupId": "BG001", "value": "1"}, {"groupId": "BG002", "value": "3"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "SECONDARY", "title": "Change in Systolic Blood Pressure From Baseline to Week 6", "populationDescription": "416 and 373 - number of patients that received at least one dose of study medication and had 1 follow-up visit (ITT population). Information available for 392 and 344 patients at week 6 for Losartan 50/HCTZ 12.5mg and Valsartan 80/HCTZ 12.5mg respectively", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "mm Hg", "timeFrame": "Baseline and Week 6", "groups": [{"id": "OG000", "title": "Losartan 50 mg/HCTZ 12.5 mg", "description": "Patients could be titrated up from losartan 50 mg/hydrochlorothiazide (HCTZ) 12.5 mg to losartan 100 mg/HCTZ 25 mg only if needed to achieve target blood pressure."}, {"id": "OG001", "title": "Valsartan 80 mg/HCTZ 12.5 mg", "description": "Patients could be titrated up from valsartan 80 mg/HCTZ 12.5 mg to valsartan 160 mg/HCTZ 25 mg only if needed to achieve target blood pressure."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "392"}, {"groupId": "OG001", "value": "344"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-16.7", "spread": "14.70"}, {"groupId": "OG001", "value": "-18.2", "spread": "13.84"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "pValue": "0.153", "statisticalMethod": "ANOVA", "ciPctValue": "95"}]}, {"type": "SECONDARY", "title": "Change in Diastolic Blood Pressure From Baseline to Week 6", "populationDescription": "416 and 373 - number of patients that received at least one dose of study medication and had 1 follow-up visit (ITT population). Information available for 392 and 344 patients at week 6 for Losartan 50/HCTZ 12.5mg and Valsartan 80/HCTZ 12.5mg respectively", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "mm Hg", "timeFrame": "Baseline and Week 6", "groups": [{"id": "OG000", "title": "Losartan 50 mg/HCTZ 12.5 mg", "description": "Patients could be titrated up from losartan 50 mg/hydrochlorothiazide (HCTZ) 12.5 mg to losartan 100 mg/HCTZ 25 mg only if needed to achieve target blood pressure."}, {"id": "OG001", "title": "Valsartan 80 mg/HCTZ 12.5 mg", "description": "Patients could be titrated up from valsartan 80 mg/HCTZ 12.5 mg to valsartan 160 mg/HCTZ 25 mg only if needed to achieve target blood pressure."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "392"}, {"groupId": "OG001", "value": "344"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-8.4", "spread": "9.35"}, {"groupId": "OG001", "value": "-9.1", "spread": "9.16"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "pValue": "0.343", "statisticalMethod": "ANOVA", "ciPctValue": "95"}]}, {"type": "SECONDARY", "title": "Number of Patients Achieving Target Blood Pressure at Week 6", "description": "Number of Patients Achieving Target Blood Pressure (\\<140/90 mm Hg and \\<130/80 mm Hg for diabetics) at week 6", "populationDescription": "416 and 373 - number of patients that received at least one dose of study medication and had 1 follow-up visit (ITT population). Information available for 393 and 345 patients at week 6 for Losartan 50/HCTZ 12.5mg and Valsartan 80/HCTZ 12.5mg respectively", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Patients", "timeFrame": "Week 6", "groups": [{"id": "OG000", "title": "Losartan 50 mg/HCTZ 12.5 mg", "description": "Patients could be titrated up from losartan 50 mg/hydrochlorothiazide (HCTZ) 12.5 mg to losartan 100 mg/HCTZ 25 mg only if needed to achieve target blood pressure."}, {"id": "OG001", "title": "Valsartan 80 mg/HCTZ 12.5 mg", "description": "Patients could be titrated up from valsartan 80 mg/HCTZ 12.5 mg to valsartan 160 mg/HCTZ 25 mg only if needed to achieve target blood pressure."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "393"}, {"groupId": "OG001", "value": "345"}]}], "classes": [{"title": "Achieved Target Blood Pressure", "categories": [{"measurements": [{"groupId": "OG000", "value": "253"}, {"groupId": "OG001", "value": "241"}]}]}, {"title": "Did Not Achieve Target Blood Pressure", "categories": [{"measurements": [{"groupId": "OG000", "value": "140"}, {"groupId": "OG001", "value": "104"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "pValue": "0.118", "statisticalMethod": "Fisher Exact", "ciPctValue": "95"}]}, {"type": "PRIMARY", "title": "Change in Systolic Blood Pressure From Baseline to Week 12", "populationDescription": "416 and 373 - number of patients that received at least one dose of study medication and had 1 follow-up visit (ITT population). Information available for 371 and 331 patients at week 12 for Losartan 50/HCTZ 12.5mg and Valsartan 80/HCTZ 12.5mg respectively", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "mm Hg", "timeFrame": "Baseline and Week 12", "groups": [{"id": "OG000", "title": "Losartan 50 mg/HCTZ 12.5 mg", "description": "Patients could be titrated up from losartan 50 mg/hydrochlorothiazide (HCTZ) 12.5 mg to losartan 100 mg/HCTZ 25 mg only if needed to achieve target blood pressure."}, {"id": "OG001", "title": "Valsartan 80 mg/HCTZ 12.5 mg", "description": "Patients could be titrated up from valsartan 80 mg/HCTZ 12.5 mg to valsartan 160 mg/HCTZ 25 mg only if needed to achieve target blood pressure."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "371"}, {"groupId": "OG001", "value": "331"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-19.9", "spread": "13.79"}, {"groupId": "OG001", "value": "-20.8", "spread": "13.61"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "pValue": "0.395", "statisticalMethod": "ANOVA", "ciPctValue": "95"}]}, {"type": "SECONDARY", "title": "Number of Patients Achieving Target Blood Pressure at Week 12", "description": "Number of Patients Achieving Target Blood Pressure (\\<140/90 mm Hg and \\<130/80 mm Hg for diabetics) at week 12", "populationDescription": "416 and 373 - number of patients that received at least one dose of study medication and had 1 follow-up visit (ITT population). Information available for 372 and 332 patients at week 12 for Losartan 50/HCTZ 12.5mg and Valsartan 80/HCTZ 12.5mg respectively", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Patients", "timeFrame": "12 Weeks", "groups": [{"id": "OG000", "title": "Losartan 50 mg/HCTZ 12.5 mg", "description": "Patients could be titrated up from losartan 50 mg/hydrochlorothiazide (HCTZ) 12.5 mg to losartan 100 mg/HCTZ 25 mg only if needed to achieve target blood pressure."}, {"id": "OG001", "title": "Valsartan 80 mg/HCTZ 12.5 mg", "description": "Patients could be titrated up from valsartan 80 mg/HCTZ 12.5 mg to valsartan 160 mg/HCTZ 25 mg only if needed to achieve target blood pressure."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "372"}, {"groupId": "OG001", "value": "332"}]}], "classes": [{"title": "Achieved Target Blood Pressure", "categories": [{"measurements": [{"groupId": "OG000", "value": "278"}, {"groupId": "OG001", "value": "253"}]}]}, {"title": "Did Not Achieve Target Blood Pressure", "categories": [{"measurements": [{"groupId": "OG000", "value": "94"}, {"groupId": "OG001", "value": "79"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "pValue": "0.662", "statisticalMethod": "Fisher Exact", "ciPctValue": "95"}]}, {"type": "SECONDARY", "title": "Time to Achieve Target Blood Pressure", "description": "Time to achieve the target blood pressure (\\<140/90 mmHg and \\<130/80 mmHg for diabetics)", "populationDescription": "416 and 373 - number of patients that received at least one dose of study medication and had 1 follow-up visit (ITT population). Information available for 406 and 360 patients for Losartan 50/HCTZ 12.5mg and Valsartan 80/HCTZ 12.5mg respectively", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "Days", "timeFrame": "12 weeks", "groups": [{"id": "OG000", "title": "Losartan 50 mg/HCTZ 12.5 mg", "description": "Patients could be titrated up from losartan 50 mg/hydrochlorothiazide (HCTZ) 12.5 mg to losartan 100 mg/HCTZ 25 mg only if needed to achieve target blood pressure."}, {"id": "OG001", "title": "Valsartan 80 mg/HCTZ 12.5 mg", "description": "Patients could be titrated up from valsartan 80 mg/HCTZ 12.5 mg to valsartan 160 mg/HCTZ 25 mg only if needed to achieve target blood pressure."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "406"}, {"groupId": "OG001", "value": "360"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "62.3", "spread": "1.44"}, {"groupId": "OG001", "value": "57.3", "spread": "1.24"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "pValue": "0.020", "statisticalMethod": "Log Rank", "ciPctValue": "95"}]}, {"type": "SECONDARY", "title": "Change in Uric Acid From Baseline to Week 6", "populationDescription": "416 and 373 - number of patients that received at least one dose of study medication and had 1 follow-up visit (ITT population). Information available for 298 and 269 patients at week 6 for Losartan 50/HCTZ 12.5mg and Valsartan 80/HCTZ 12.5mg respectively", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "umol/L", "timeFrame": "Baseline and Week 6", "groups": [{"id": "OG000", "title": "Losartan 50 mg/HCTZ 12.5 mg", "description": "Patients could be titrated up from losartan 50 mg/hydrochlorothiazide (HCTZ) 12.5 mg to losartan 100 mg/HCTZ 25 mg only if needed to achieve target blood pressure."}, {"id": "OG001", "title": "Valsartan 80 mg/HCTZ 12.5 mg", "description": "Patients could be titrated up from valsartan 80 mg/HCTZ 12.5 mg to valsartan 160 mg/HCTZ 25 mg only if needed to achieve target blood pressure."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "298"}, {"groupId": "OG001", "value": "269"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.3", "spread": "53.12"}, {"groupId": "OG001", "value": "21.7", "spread": "55.09"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "pValue": "<0.001", "statisticalMethod": "ANOVA", "ciPctValue": "95"}]}, {"type": "PRIMARY", "title": "Change in Diastolic Blood Pressure From Baseline to Week 12", "populationDescription": "416 and 373 - number of patients that received at least one dose of study medication and had 1 follow-up visit (ITT population). Information available for 371 and 331 patients at week 12 for Losartan 50/HCTZ 12.5mg and Valsartan 80/HCTZ 12.5mg respectively", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "mm Hg", "timeFrame": "Baseline and Week 12", "groups": [{"id": "OG000", "title": "Losartan 50 mg/HCTZ 12.5 mg", "description": "Patients could be titrated up from losartan 50 mg/hydrochlorothiazide (HCTZ) 12.5 mg to losartan 100 mg/HCTZ 25 mg only if needed to achieve target blood pressure."}, {"id": "OG001", "title": "Valsartan 80 mg/HCTZ 12.5 mg", "description": "Patients could be titrated up from valsartan 80 mg/HCTZ 12.5 mg to valsartan 160 mg/HCTZ 25 mg only if needed to achieve target blood pressure."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "371"}, {"groupId": "OG001", "value": "331"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-10.6", "spread": "9.28"}, {"groupId": "OG001", "value": "-10.5", "spread": "9.58"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "pValue": "0.935", "statisticalMethod": "ANOVA", "ciPctValue": "95"}]}, {"type": "SECONDARY", "title": "Change in Uric Acid From Baseline to Week 12", "populationDescription": "416 and 373 - number of patients that received at least one dose of study medication and had 1 follow-up visit (ITT population). Information available for 286 and 253 patients at week 12 for Losartan 50/HCTZ 12.5mg and Valsartan 80/HCTZ 12.5mg respectively", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "umol/L", "timeFrame": "Baseline and Week 12", "groups": [{"id": "OG000", "title": "Losartan 50 mg/HCTZ 12.5 mg", "description": "Patients could be titrated up from losartan 50 mg/hydrochlorothiazide (HCTZ) 12.5 mg to losartan 100 mg/HCTZ 25 mg only if needed to achieve target blood pressure."}, {"id": "OG001", "title": "Valsartan 80 mg/HCTZ 12.5 mg", "description": "Patients could be titrated up from valsartan 80 mg/HCTZ 12.5 mg to valsartan 160 mg/HCTZ 25 mg only if needed to achieve target blood pressure."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "286"}, {"groupId": "OG001", "value": "253"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-0.4", "spread": "57.02"}, {"groupId": "OG001", "value": "29.9", "spread": "64.79"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "pValue": "<0.001", "statisticalMethod": "ANOVA", "ciPctValue": "95"}]}, {"type": "SECONDARY", "title": "Change in Serum Highly Sensitive C-reactive Protein From Baseline to Week 6", "populationDescription": "416 and 373 - number of patients that received at least one dose of study medication and had 1 follow-up visit (ITT population). Information available for 304 and 272 patients at week 6 for Losartan 50/HCTZ 12.5mg and Valsartan 80/HCTZ 12.5mg respectively", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "mg/L", "timeFrame": "Baseline and Week 6", "groups": [{"id": "OG000", "title": "Losartan 50 mg/HCTZ 12.5 mg", "description": "Patients could be titrated up from losartan 50 mg/hydrochlorothiazide (HCTZ) 12.5 mg to losartan 100 mg/HCTZ 25 mg only if needed to achieve target blood pressure."}, {"id": "OG001", "title": "Valsartan 80 mg/HCTZ 12.5 mg", "description": "Patients could be titrated up from valsartan 80 mg/HCTZ 12.5 mg to valsartan 160 mg/HCTZ 25 mg only if needed to achieve target blood pressure."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "304"}, {"groupId": "OG001", "value": "272"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.8", "spread": "26.21"}, {"groupId": "OG001", "value": "0.6", "spread": "6.60"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "pValue": "0.899", "statisticalMethod": "ANOVA", "ciPctValue": "95"}]}, {"type": "SECONDARY", "title": "Change in Serum Highly Sensitive C-reactive Protein From Baseline to Week 12", "populationDescription": "416 and 373 - number of patients that received at least one dose of study medication and had 1 follow-up visit (ITT population). Information available for 279 and 255 patients at week 12 for Losartan 50/HCTZ 12.5mg and Valsartan 80/HCTZ 12.5mg respectively", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "umol/L", "timeFrame": "Baseline and Week 12", "groups": [{"id": "OG000", "title": "Losartan 50 mg/HCTZ 12.5 mg", "description": "Patients could be titrated up from losartan 50 mg/hydrochlorothiazide (HCTZ) 12.5 mg to losartan 100 mg/HCTZ 25 mg only if needed to achieve target blood pressure."}, {"id": "OG001", "title": "Valsartan 80 mg/HCTZ 12.5 mg", "description": "Patients could be titrated up from valsartan 80 mg/HCTZ 12.5 mg to valsartan 160 mg/HCTZ 25 mg only if needed to achieve target blood pressure."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "279"}, {"groupId": "OG001", "value": "255"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-0.3", "spread": "8.05"}, {"groupId": "OG001", "value": "0.5", "spread": "7.20"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "pValue": "0.218", "statisticalMethod": "ANOVA", "ciPctValue": "95"}]}, {"type": "SECONDARY", "title": "Change in Gamma-Glutamyl Transpeptidase (Gamma-GT) From Baseline to Week 6", "populationDescription": "416 and 373 - number of patients that received at least one dose of study medication and had 1 follow-up visit (ITT population). Information available for 300 and 273 patients at week 6 for Losartan 50/HCTZ 12.5mg and Valsartan 80/HCTZ 12.5mg respectively", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "IU/L", "timeFrame": "Baseline and Week 6", "groups": [{"id": "OG000", "title": "Losartan 50 mg/HCTZ 12.5 mg", "description": "Patients could be titrated up from losartan 50 mg/hydrochlorothiazide (HCTZ) 12.5 mg to losartan 100 mg/HCTZ 25 mg only if needed to achieve target blood pressure."}, {"id": "OG001", "title": "Valsartan 80 mg/HCTZ 12.5 mg", "description": "Patients could be titrated up from valsartan 80 mg/HCTZ 12.5 mg to valsartan 160 mg/HCTZ 25 mg only if needed to achieve target blood pressure."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "300"}, {"groupId": "OG001", "value": "273"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-1.8", "spread": "21.20"}, {"groupId": "OG001", "value": "-0.1", "spread": "24.71"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "pValue": "0.386", "statisticalMethod": "ANOVA", "ciPctValue": "95"}]}, {"type": "SECONDARY", "title": "Change in Gamma-Glutamyl Transpeptidase (Gamma-GT) From Baseline to Week 12", "populationDescription": "416 and 373 - number of patients that received at least one dose of study medication and had 1 follow-up visit (ITT population). Information available for 279 and 254 patients at week 12 for Losartan 50/HCTZ 12.5mg and Valsartan 80/HCTZ 12.5mg respectively", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "IU/L", "timeFrame": "Baseline and Week 12", "groups": [{"id": "OG000", "title": "Losartan 50 mg/HCTZ 12.5 mg", "description": "Patients could be titrated up from losartan 50 mg/hydrochlorothiazide (HCTZ) 12.5 mg to losartan 100 mg/HCTZ 25 mg only if needed to achieve target blood pressure."}, {"id": "OG001", "title": "Valsartan 80 mg/HCTZ 12.5 mg", "description": "Patients could be titrated up from valsartan 80 mg/HCTZ 12.5 mg to valsartan 160 mg/HCTZ 25 mg only if needed to achieve target blood pressure."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "279"}, {"groupId": "OG001", "value": "254"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-0.7", "spread": "21.44"}, {"groupId": "OG001", "value": "-0.0", "spread": "24.45"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "pValue": "0.725", "statisticalMethod": "ANOVA", "ciPctValue": "95"}]}]}, "adverseEventsModule": {"frequencyThreshold": "0", "eventGroups": [{"id": "EG000", "title": "Losartan 50 mg/HCTZ 12.5 mg", "description": "Patients could be titrated up from losartan 50 mg/hydrochlorothiazide (HCTZ) 12.5 mg to losartan 100 mg/HCTZ 25 mg only if needed to achieve target blood pressure.", "seriousNumAffected": 11, "seriousNumAtRisk": 425, "otherNumAffected": 56, "otherNumAtRisk": 425}, {"id": "EG001", "title": "Valsartan 80 mg/HCTZ 12.5 mg", "description": "Patients could be titrated up from valsartan 80 mg/HCTZ 12.5 mg to valsartan 160 mg/HCTZ 25 mg only if needed to achieve target blood pressure.", "seriousNumAffected": 5, "seriousNumAtRisk": 383, "otherNumAffected": 57, "otherNumAtRisk": 383}], "seriousEvents": [{"term": "Acute myocardial infarction", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 12.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 425}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 383}]}, {"term": "Barrett's oesophagus", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 12.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 425}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 383}]}, {"term": "Gastrointestinal haemorrhage", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 12.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 425}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 383}]}, {"term": "Chest pain", "organSystem": "General disorders", "sourceVocabulary": "MedDRA 12.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 425}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 383}]}, {"term": "Pneumonia klebsiella", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 12.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 425}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 383}]}, {"term": "Cholecystitis acute", "organSystem": "Hepatobiliary disorders", "sourceVocabulary": "MedDRA 12.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 425}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 383}]}, {"term": "Lung neoplasm", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA 12.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 425}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 383}]}, {"term": "Multiple myeloma", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA 12.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 425}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 383}]}, {"term": "Cerebrovascular accident", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 12.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 425}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 383}]}, {"term": "Critical illness polyneuropathy", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 12.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 425}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 383}]}, {"term": "Syncope", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 12.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 425}, {"groupId": "EG001", "numEvents": 2, "numAffected": 2, "numAtRisk": 383}]}, {"term": "Completed suicide", "organSystem": "Psychiatric disorders", "sourceVocabulary": "MedDRA 12.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 425}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 383}]}, {"term": "Renal failure", "organSystem": "Renal and urinary disorders", "sourceVocabulary": "MedDRA 12.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 425}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 383}]}, {"term": "Renal failure acute", "organSystem": "Renal and urinary disorders", "sourceVocabulary": "MedDRA 12.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 425}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 383}]}, {"term": "Pulmonary oedema", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 12.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 425}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 383}]}], "otherEvents": [{"term": "Vertigo", "organSystem": "Ear and labyrinth disorders", "sourceVocabulary": "MedDRA 12.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 425}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 383}]}, {"term": "Visual disturbance", "organSystem": "Eye disorders", "sourceVocabulary": "MedDRA 12.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 425}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 383}]}, {"term": "Abdominal discomfort", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 12.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 425}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 383}]}, {"term": "Abdominal pain upper", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 12.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 3, "numAffected": 3, "numAtRisk": 425}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 383}]}, {"term": "Diarrhoea", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 12.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 3, "numAffected": 3, "numAtRisk": 425}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 383}]}, {"term": "Dyspepsia", "organSystem": "General disorders", "sourceVocabulary": "MedDRA 12.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 425}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 383}]}, {"term": "Gastritis", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 12.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 425}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 383}]}, {"term": "Gastrointestinal disorder", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 12.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 425}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 383}]}, {"term": "Nausea", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 12.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 425}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 383}]}, {"term": "Stomach discomfort", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 12.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 2, "numAtRisk": 425}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 383}]}, {"term": "Swollen tongue", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 12.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 425}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 383}]}, {"term": "Vomiting", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 12.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 425}, {"groupId": "EG001", "numEvents": 2, "numAffected": 2, "numAtRisk": 383}]}, {"term": "Asthenia", "organSystem": "General disorders", "sourceVocabulary": "MedDRA 12.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 425}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 383}]}, {"term": "Chest discomfort", "organSystem": "General disorders", "sourceVocabulary": "MedDRA 12.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 425}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 383}]}, {"term": "Chest pain", "organSystem": "General disorders", "sourceVocabulary": "MedDRA 12.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 425}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 383}]}, {"term": "Fatigue", "organSystem": "General disorders", "sourceVocabulary": "MedDRA 12.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 425}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 383}]}, {"term": "Feeling abnormal", "organSystem": "General disorders", "sourceVocabulary": "MedDRA 12.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 425}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 383}]}, {"term": "Inflammation", "organSystem": "General disorders", "sourceVocabulary": "MedDRA 12.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 425}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 383}]}, {"term": "Malaise", "organSystem": "General disorders", "sourceVocabulary": "MedDRA 12.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 425}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 383}]}, {"term": "Pain", "organSystem": "General disorders", "sourceVocabulary": "MedDRA 12.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 425}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 383}]}, {"term": "Slugishness", "organSystem": "General disorders", "sourceVocabulary": "MedDRA 12.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 425}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 383}]}, {"term": "Hypersensitivity", "organSystem": "Immune system disorders", "sourceVocabulary": "MedDRA 12.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 425}, {"groupId": "EG001", "numEvents": 2, "numAffected": 2, "numAtRisk": 383}]}, {"term": "Bronchitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 12.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 425}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 383}]}, {"term": "Gastroenteritis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 12.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 425}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 383}]}, {"term": "Helicobacter infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 12.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 425}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 383}]}, {"term": "Influenza", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 12.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 425}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 383}]}, {"term": "Mastitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 12.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 425}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 383}]}, {"term": "Rhinitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 12.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 425}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 383}]}, {"term": "Sinusitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 12.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 425}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 383}]}, {"term": "Upper respiratory tract infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 12.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 425}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 383}]}, {"term": "Back injury", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 12.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 425}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 383}]}, {"term": "Back sprain", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 12.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 425}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 383}]}, {"term": "Incorrect does administered", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 12.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 425}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 383}]}, {"term": "Neck injury", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 12.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 425}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 383}]}, {"term": "Wrong technique in drug usage process", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 12.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 425}, {"groupId": "EG001", "numEvents": 2, "numAffected": 2, "numAtRisk": 383}]}, {"term": "Blood creatinine increased", "organSystem": "Investigations", "sourceVocabulary": "MedDRA 12.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 2, "numAtRisk": 425}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 383}]}, {"term": "Blood glucose increased", "organSystem": "Investigations", "sourceVocabulary": "MedDRA 12.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 425}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 383}]}, {"term": "Blood potassium abnormal", "organSystem": "Investigations", "sourceVocabulary": "MedDRA 12.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 425}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 383}]}, {"term": "Blood potassium increased", "organSystem": "Investigations", "sourceVocabulary": "MedDRA 12.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 3, "numAffected": 3, "numAtRisk": 425}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 383}]}, {"term": "Blood pressure decreased", "organSystem": "Investigations", "sourceVocabulary": "MedDRA 12.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 425}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 383}]}, {"term": "C-Reactive protein increased", "organSystem": "Investigations", "sourceVocabulary": "MedDRA 12.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 7, "numAffected": 7, "numAtRisk": 425}, {"groupId": "EG001", "numEvents": 3, "numAffected": 3, "numAtRisk": 383}]}, {"term": "Cardiac murmur", "organSystem": "Investigations", "sourceVocabulary": "MedDRA 12.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 425}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 383}]}, {"term": "Gamma-glutamyltransferase increased", "organSystem": "Investigations", "sourceVocabulary": "MedDRA 12.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 425}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 383}]}, {"term": "Heart rate increased", "organSystem": "Investigations", "sourceVocabulary": "MedDRA 12.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 425}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 383}]}, {"term": "Dehydration", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA 12.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 425}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 383}]}, {"term": "Diabetes mellitus", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA 12.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 425}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 383}]}, {"term": "Hyperkalemia", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA 12.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 425}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 383}]}, {"term": "Hypokalemia", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA 12.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 425}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 383}]}, {"term": "Arthralgia", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 12.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 2, "numAtRisk": 425}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 383}]}, {"term": "Back pain", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 12.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 425}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 383}]}, {"term": "Joint stiffness", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 12.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 425}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 383}]}, {"term": "Myalgia", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 12.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 425}, {"groupId": "EG001", "numEvents": 2, "numAffected": 2, "numAtRisk": 383}]}, {"term": "Pain in extremity", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 12.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 425}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 383}]}, {"term": "Dizziness", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 12.0", "stats": [{"groupId": "EG000", "numEvents": 3, "numAffected": 3, "numAtRisk": 425}, {"groupId": "EG001", "numEvents": 4, "numAffected": 4, "numAtRisk": 383}]}, {"term": "Headache", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 12.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 4, "numAffected": 4, "numAtRisk": 425}, {"groupId": "EG001", "numEvents": 4, "numAffected": 4, "numAtRisk": 383}]}, {"term": "Tremor", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 12.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 425}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 383}]}, {"term": "Anxiety", "organSystem": "Psychiatric disorders", "sourceVocabulary": "MedDRA 12.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 425}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 383}]}, {"term": "Depression", "organSystem": "Psychiatric disorders", "sourceVocabulary": "MedDRA 12.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 425}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 383}]}, {"term": "Mood swings", "organSystem": "Psychiatric disorders", "sourceVocabulary": "MedDRA 12.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 425}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 383}]}, {"term": "Renal impairment", "organSystem": "Psychiatric disorders", "sourceVocabulary": "MedDRA 12.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 425}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 383}]}, {"term": "Urinary retention", "organSystem": "Renal and urinary disorders", "sourceVocabulary": "MedDRA 12.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 425}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 383}]}, {"term": "Cough", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 12.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 2, "numAtRisk": 425}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 383}]}, {"term": "Dyspnoea", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 12.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 425}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 383}]}, {"term": "Productive cough", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 12.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 425}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 383}]}, {"term": "Night sweats", "organSystem": "Skin and subcutaneous tissue disorders", "sourceVocabulary": "MedDRA 12.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 425}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 383}]}, {"term": "Swelling face", "organSystem": "Skin and subcutaneous tissue disorders", "sourceVocabulary": "MedDRA 12.0", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 425}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 383}]}, {"term": "Inguinal hernia repair", "organSystem": "Surgical and medical procedures", "sourceVocabulary": "MedDRA 12.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 425}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 383}]}, {"term": "Hot flush", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA 12.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 425}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 383}]}, {"term": "Hypotension", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA 12.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 425}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 383}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictionType": "OTHER", "restrictiveAgreement": true, "otherDetails": "Merck agreements may vary with individual investigators, but will not prohibit any investigator from publishing. Merck supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial."}, "pointOfContact": {"title": "Senior Vice President, Global Clinical Development", "organization": "Merck Sharp & Dohme Corp", "phone": "1-800-672-6372"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-07-01", "removedCountries": ["Canada"]}, "conditionBrowseModule": {"meshes": [{"id": "D000006973", "term": "Hypertension"}, {"id": "D000075222", "term": "Essential Hypertension"}], "ancestors": [{"id": "D000014652", "term": "Vascular Diseases"}, {"id": "D000002318", "term": "Cardiovascular Diseases"}], "browseLeaves": [{"id": "M10024", "name": "Hypertension", "asFound": "Hypertension", "relevance": "HIGH"}, {"id": "M1470", "name": "Essential Hypertension", "asFound": "Essential Hypertension", "relevance": "HIGH"}, {"id": "M17400", "name": "Vascular Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC14", "name": "Heart and Blood Diseases"}, {"abbrev": "All", "name": "All Conditions"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000019808", "term": "Losartan"}, {"id": "D000068756", "term": "Valsartan"}, {"id": "D000006852", "term": "Hydrochlorothiazide"}], "ancestors": [{"id": "D000000959", "term": "Antihypertensive Agents"}, {"id": "D000047228", "term": "Angiotensin II Type 1 Receptor Blockers"}, {"id": "D000057911", "term": "Angiotensin Receptor Antagonists"}, {"id": "D000045504", "term": "Molecular Mechanisms of Pharmacological Action"}, {"id": "D000000889", "term": "Anti-Arrhythmia Agents"}, {"id": "D000004232", "term": "Diuretics"}, {"id": "D000045283", "term": "Natriuretic Agents"}, {"id": "D000045505", "term": "Physiological Effects of Drugs"}, {"id": "D000049993", "term": "Sodium Chloride Symporter Inhibitors"}, {"id": "D000049990", "term": "Membrane Transport Modulators"}], "browseLeaves": [{"id": "M21701", "name": "Losartan", "asFound": "Gradual", "relevance": "HIGH"}, {"id": "M301", "name": "Valsartan", "asFound": "Extended", "relevance": "HIGH"}, {"id": "M9910", "name": "Hydrochlorothiazide", "asFound": "Prescription", "relevance": "HIGH"}, {"id": "M4277", "name": "Antihypertensive Agents", "relevance": "LOW"}, {"id": "M4132", "name": "Angiotensin II", "relevance": "LOW"}, {"id": "M289354", "name": "Giapreza", "relevance": "LOW"}, {"id": "M4135", "name": "Angiotensinogen", "relevance": "LOW"}, {"id": "M25789", "name": "Angiotensin II Type 1 Receptor Blockers", "relevance": "LOW"}, {"id": "M28916", "name": "Angiotensin Receptor Antagonists", "relevance": "LOW"}, {"id": "M4213", "name": "Anti-Arrhythmia Agents", "relevance": "LOW"}, {"id": "M7411", "name": "Diuretics", "relevance": "LOW"}, {"id": "M26152", "name": "Sodium Chloride Symporter Inhibitors", "relevance": "LOW"}], "browseBranches": [{"abbrev": "AnArAg", "name": "Anti-Arrhythmia Agents"}, {"abbrev": "AnAg", "name": "Antihypertensive Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}, {"abbrev": "NaAg", "name": "Natriuretic Agents"}, {"abbrev": "VaCoAg", "name": "Vasoconstrictor Agents"}]}}, "hasResults": true}